Importantly, by neutralizing IL-1β after stroke or blocking pro-inflammatory monocyte migration using a C-C chemokine receptor type 2 and 5 antagonist, post-stroke cardiac dysfunction could be prevented. This evidence concerns the gene IL1B and stroke disorder.